Rheumatoid Arthritis Clinical Trial

TITLE:
A Phase 4, Multicenter, Open-label, Assessor-blinded, Switch Study of the Efficacy and Safety of Infliximab (Remicade) in Patients With Active Rheumatoid Arthritis (RA) Who are Responding Inadequaltely to Etanercept (Enbrel) or Adalimumab

PURPOSE:
To evaluate the efficacy of infliximab at week 10 in patients with active RA who are having an inadequate response to therapy with etanercept or adalimumab

PHASE:
4

INSTITUTIONAL REVIEW BOARD:
Copernicus

STATUS:
Closed to enrollment

ELIGIBILITY:
Patients aged 18 years or more with active RA who are receiving methotrexate and having inadequate response to current anti-TNF alpha therapy with etanercept or adalimumab

DURATION:
30 weeks

Principal Investigator:
Eric S. Leiberman, MD

CONTACT:
Isabella Rodrigues, PhD
Clinical Research Coordinator
908-277-8630